DDR1
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Y Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: Y Sites / Y Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A6NHL2 | Y319 | Sugiyama | TUBAL3 | TTACFESSNQLVKCDPRLGKyMACCLLyRGDVVPKEVNAAI |
| O00469 | Y444 | Sugiyama | PLOD2 | LWSNFWGALSPDGYYARsEDyVDIVQGNRVGVWNVPYMANV |
| O43390 | Y376 | Sugiyama | HNRNPR HNRPR | ILEKSFSEFGKLERVKKLKDyAFVHFEDRGAAVKAMDEMNG |
| O60506 | Y373 | Sugiyama | SYNCRIP HNRPQ NSAP1 | ILEKAFsQFGKLERVKKLKDyAFIHFDERDGAVKAMEEMNG |
| O60814 | Y38 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | AVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| O75369 | Y1576 | Sugiyama | FLNB FLN1L FLN3 TABP TAP | ITDQEGKPKRAIVHDNKDGtyAVtyIPDKtGRYMIGVTYGG |
| P00558 | Y161 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | KAEPAKIEAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNL |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P06493 | T161 | EPSD | CDK1 CDC2 CDC28A CDKN1 P34CDC2 | tIKLADFGLARAFGIPIRVytHEVVTLWYRSPEVLLGsARY |
| P06733 | Y44 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | LFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGKGVSK |
| P07205 | Y161 | Sugiyama | PGK2 PGKB | KAEPDKIEAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNL |
| P07437 | Y50 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | IDPTGtyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEP |
| P07900 | Y309 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | ELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHF |
| P07900 | Y313 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | tKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P07900 | Y492 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEMVsLKDYCTRMKENQKHIyyItGETKDQVANsAFVERLR |
| P08238 | Y301 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | ELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHF |
| P08238 | Y305 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | tKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLAVKHFSVEG |
| P08238 | Y484 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEMtsLsEyVsRMKEtQKsIyyItGEsKEQVANsAFVERVR |
| P08865 | Y156 | Sugiyama | RPSA LAMBR LAMR1 | EAsyVNLPtIALCNTDSPLRyVDIAIPCNNKGAHSVGLMWW |
| P09234 | Y8 | Sugiyama | SNRPC | _____________MPKFyCDyCDtyLtHDsPsVRKTHCSGR |
| P10809 | Y243 | Sugiyama | HSPD1 HSP60 | yIsPyFINtsKGQKCEFQDAyVLLsEKKIssIQsIVPALEI |
| P11142 | S40 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P13639 | Y730 | Sugiyama | EEF2 EF2 | HADAIHRGGGQIIPtARRCLyAsVLtAQPRLMEPIyLVEIQ |
| P17066 | S42 | Sugiyama | HSPA6 HSP70B' | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P18669 | Y142 | Sugiyama | PGAM1 PGAMA CDABP0006 | PPPPMEPDHPFysNIsKDRRyADLtEDQLPsCEsLKDtIAR |
| P24941 | T160 | EPSD | CDK2 CDKN2 | AIKLADFGLARAFGVPVRtytHEVVtLWyRAPEILLGCKYY |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P30101 | Y100 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | LAKVDCTANTNTCNKyGVsGyPtLKIFRDGEEAGAyDGPRt |
| P31939 | Y362 | Sugiyama | ATIC PURH OK/SW-cl.86 | IAPGyEEEALTILSKKKNGNyCVLQMDQsYKPDENEVRTLF |
| P32119 | Y115 | Sugiyama | PRDX2 NKEFB TDPX1 | GLGPLNIPLLADVTRRLsEDyGVLKTDEGIAYRGLFIIDGK |
| P34931 | S42 | Sugiyama | HSPA1L | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P39019 | Y48 | Sugiyama | RPS19 | LKVPEWVDtVKLAKHKELAPyDENWFytRAAstARHLYLRG |
| P43121 | Y222 | Sugiyama | MCAM MUC18 | YTLQSILKAQLVKEDKDAQFyCELNYRLPSGNHMKEsREVT |
| P47756 | Y59 | Sugiyama | CAPZB | LLSSVDQPLKIARDKVVGKDyLLCDyNRDGDSyRsPWSNKy |
| P48741 | S42 | Sugiyama | HSPA7 HSP70B | VFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQAA |
| P52788 | Y336 | Sugiyama | SMS | GNCVNLTEALSLYEEQLGRLyCPVEFSKEIVCVPSYLELWV |
| P54652 | S41 | Sugiyama | HSPA2 | VFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQVA |
| P57053 | Y38 | Sugiyama | H2BC12L H2BFS H2BS1 | AVTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| P58876 | Y38 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | AVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| P60660 | Y89 | Sugiyama | MYL6 | HFLPMLQTVAKNKDQGtyEDyVEGLRVFDKEGNGtVMGAEI |
| P62269 | Y95 | Sugiyama | RPS18 D6S218E | RQYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLK |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62750 | Y144 | Sugiyama | RPL23A | VNtLIRPDGEKKAYVRLAPDyDALDVANKIGII________ |
| P62750 | Y74 | Sugiyama | RPL23A | LRRQPKYPRKSAPRRNKLDHyAIIKFPLTTEsAMKKIEDNN |
| P62807 | Y38 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | AVTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIssK |
| P62826 | Y146 | Sugiyama | RAN ARA24 OK/SW-cl.81 | IKDRKVKAKsIVFHRKKNLQyyDIsAKSNyNFEKPFLWLAR |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P68363 | Y312 | Sugiyama | TUBA1B | tNACFEPANQMVKCDPRHGKyMACCLLyRGDVVPKDVNAAI |
| P68363 | Y432 | Sugiyama | TUBA1B | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| P68366 | Y312 | Sugiyama | TUBA4A TUBA1 | tNACFEPANQMVKCDPRHGKyMACCLLyRGDVVPKDVNAAI |
| Q06830 | Y116 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | GLGPMNIPLVSDPKRtIAQDyGVLKADEGIsFRGLFIIDDK |
| Q08345 | Y513 | SIGNOR|EPSD | DDR1 CAK EDDR1 NEP NTRK4 PTK3A RTK6 TRKE | PPHSAPCVPNGSALLLSNPAyRLLLATyARPPRGPGPPTPA |
| Q08345 | Y569 | PSP | DDR1 CAK EDDR1 NEP NTRK4 PTK3A RTK6 TRKE | EPEKPGAPLLPPPPQNSVPHyAEADIVTLQGVTGGNTyAVP |
| Q08345 | Y586 | PSP | DDR1 CAK EDDR1 NEP NTRK4 PTK3A RTK6 TRKE | VPHyAEADIVTLQGVTGGNTyAVPALPPGAVGDGPPRVDFP |
| Q08345 | Y797 | Sugiyama | DDR1 CAK EDDR1 NEP NTRK4 PTK3A RTK6 TRKE | NFTIKIADFGMsRNLyAGDyyRVQGRAVLPIRWMAWECILM |
| Q12931 | Y498 | Sugiyama | TRAP1 HSP75 HSPC5 | GQLtsLsEyASRMRAGtRNIyyLCAPNRHLAEHsPyyEAMK |
| Q14257 | Y311 | Sugiyama | RCN2 ERC55 | NPDLFLtsEAtDyGRQLHDDyFyHDEL______________ |
| Q15375 | Y608 | Sugiyama | EPHA7 EHK3 HEK11 | ADQEGDEELyFHFKFPGTKTyIDPEtyEDPNRAVHQFAKEL |
| Q15375 | Y614 | Sugiyama | EPHA7 EHK3 HEK11 | EELyFHFKFPGTKTyIDPEtyEDPNRAVHQFAKELDASCIK |
| Q58FF8 | Y260 | Sugiyama | HSP90AB2P HSP90BB | VRYFSVEEYVSRMKEIQKsIyyItGEsKEQVANSAFVEQVW |
| Q58FG0 | Y177 | Sugiyama | HSP90AA5P HSP90AE | GQLEELKDSRRVMKANQKHIyyItGETKDQVANSAFVECLQ |
| Q5QNW6 | Y38 | Sugiyama | H2BC18 HIST2H2BF | AVTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| Q71U36 | Y312 | Sugiyama | TUBA1A TUBA3 | tNACFEPANQMVKCDPRHGKyMACCLLyRGDVVPKDVNAAI |
| Q71U36 | Y432 | Sugiyama | TUBA1A TUBA3 | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q86W56 | Y832 | Sugiyama | PARG | DDWQRRCTEIVAIDALHFRRyLDQFVPEKMRRELNKAYCGF |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q93079 | Y38 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | AVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| Q96HE7 | S143 | Sugiyama | ERO1A ERO1L UNQ434/PRO865 | EANNLIEECEQAERLGAVDEsLsEEtQKAVLQWTKHDDSSD |
| Q99877 | Y38 | Sugiyama | H2BC15 H2BFD HIST1H2BN | AVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| Q99879 | Y38 | Sugiyama | H2BC14 H2BFE HIST1H2BM | AINKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| Q99880 | Y38 | Sugiyama | H2BC13 H2BFC HIST1H2BL | AVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIssK |
| Q9BQE3 | Y312 | Sugiyama | TUBA1C TUBA6 | TNACFEPANQMVKCDPRHGKyMACCLLyRGDVVPKDVNAAI |
| Q9BQE3 | Y432 | Sugiyama | TUBA1C TUBA6 | GMEEGEFSEAREDMAALEKDyEEVGADsADGEDEGEEy___ |
| Q9BZX2 | Y203 | Sugiyama | UCK2 UMPK | SQYITFVKPAFEEFCLPTKKyADVIIPRGADNLVAINLIVQ |
| Q9HA47 | Y205 | Sugiyama | UCK1 URK1 | TQYTTFVKPAFEEFCLPTKKyADVIIPRGVDNMVAINLIVQ |
| Q9UBR2 | Y76 | Sugiyama | CTSZ | YLSPADLPKSWDWRNVDGVNyAsItRNQHIPQYCGSCWAHA |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Recycling pathway of L1 | R-HSA-437239 | 7.721612e-11 | 10.112 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.971744e-09 | 8.705 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.014800e-08 | 7.994 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.443387e-08 | 7.841 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.371762e-08 | 7.863 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.308206e-08 | 7.883 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.056222e-08 | 7.976 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.718262e-08 | 7.765 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.411514e-08 | 7.618 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 5.540308e-08 | 7.256 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 8.229637e-08 | 7.085 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.055546e-07 | 6.977 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.444478e-07 | 6.840 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.900861e-07 | 6.721 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.230541e-07 | 6.652 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 3.461884e-07 | 6.461 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 4.730352e-07 | 6.325 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 5.845739e-07 | 6.233 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 6.583682e-07 | 6.182 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 8.427739e-07 | 6.074 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.398089e-07 | 6.027 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.079360e-06 | 5.967 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 1.342471e-06 | 5.872 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.413855e-06 | 5.850 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.568167e-06 | 5.805 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.700678e-06 | 5.769 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.038036e-06 | 5.691 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 3.560041e-06 | 5.449 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 4.491168e-06 | 5.348 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 4.414534e-06 | 5.355 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 4.143780e-06 | 5.383 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 5.238867e-06 | 5.281 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 5.590827e-06 | 5.253 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 5.718347e-06 | 5.243 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 6.229269e-06 | 5.206 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.065412e-05 | 4.972 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.996690e-06 | 5.000 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.065412e-05 | 4.972 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.313936e-05 | 4.881 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.457654e-05 | 4.836 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.747974e-05 | 4.757 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 1.917347e-05 | 4.717 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.975810e-05 | 4.704 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.975810e-05 | 4.704 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.125645e-05 | 4.673 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.508656e-05 | 4.601 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.736278e-05 | 4.563 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 3.075954e-05 | 4.512 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 3.057608e-05 | 4.515 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.025745e-05 | 4.519 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 3.400453e-05 | 4.468 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.805780e-05 | 4.420 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.224986e-05 | 4.374 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 4.224986e-05 | 4.374 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 4.487666e-05 | 4.348 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 5.449108e-05 | 4.264 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.661350e-05 | 4.247 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 6.164031e-05 | 4.210 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 6.261664e-05 | 4.203 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.306865e-05 | 4.200 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 6.841922e-05 | 4.165 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 6.855941e-05 | 4.164 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.002077e-04 | 3.999 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.179660e-04 | 3.928 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.116655e-04 | 3.952 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.187794e-04 | 3.925 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 1.270508e-04 | 3.896 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.284101e-04 | 3.891 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.399791e-04 | 3.854 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.539601e-04 | 3.813 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.586141e-04 | 3.800 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 1.733664e-04 | 3.761 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 2.195464e-04 | 3.658 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.088683e-04 | 3.680 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.272530e-04 | 3.643 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 2.462275e-04 | 3.609 | 0 | 0 |
| Immune System | R-HSA-168256 | 2.556228e-04 | 3.592 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.024267e-04 | 3.519 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 3.266806e-04 | 3.486 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 3.272247e-04 | 3.485 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.322958e-04 | 3.364 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 4.929975e-04 | 3.307 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 5.049712e-04 | 3.297 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 5.092308e-04 | 3.293 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.125048e-04 | 3.290 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 5.760191e-04 | 3.240 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 7.210158e-04 | 3.142 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 7.328349e-04 | 3.135 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 7.842027e-04 | 3.106 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.024158e-04 | 3.096 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.024158e-04 | 3.096 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.600543e-04 | 3.065 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 9.177342e-04 | 3.037 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 9.255696e-04 | 3.034 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 9.843164e-04 | 3.007 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.019886e-03 | 2.991 | 0 | 0 |
| Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization | R-HSA-180897 | 1.040759e-03 | 2.983 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.193418e-03 | 2.923 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.157623e-03 | 2.936 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 1.231928e-03 | 2.909 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 1.334795e-03 | 2.875 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 1.353801e-03 | 2.868 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.431797e-03 | 2.844 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.498154e-03 | 2.824 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.688372e-03 | 2.773 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.109041e-03 | 2.676 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.223822e-03 | 2.653 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.306272e-03 | 2.637 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.526376e-03 | 2.598 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 2.568969e-03 | 2.590 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.568969e-03 | 2.590 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 2.589998e-03 | 2.587 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 2.589998e-03 | 2.587 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 2.589998e-03 | 2.587 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 2.681874e-03 | 2.572 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 2.894237e-03 | 2.538 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 3.243751e-03 | 2.489 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.134532e-03 | 2.504 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.921803e-03 | 2.534 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.134532e-03 | 2.504 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 3.115284e-03 | 2.507 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 3.357592e-03 | 2.474 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.357592e-03 | 2.474 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 3.500059e-03 | 2.456 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 3.500059e-03 | 2.456 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.591221e-03 | 2.445 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 4.017716e-03 | 2.396 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 4.017716e-03 | 2.396 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 4.038110e-03 | 2.394 | 0 | 0 |
| Disease | R-HSA-1643685 | 4.173027e-03 | 2.380 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 4.443194e-03 | 2.352 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 4.443194e-03 | 2.352 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 4.443194e-03 | 2.352 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 4.443194e-03 | 2.352 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 4.894976e-03 | 2.310 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.214420e-03 | 2.207 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 6.214420e-03 | 2.207 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 5.879205e-03 | 2.231 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.879205e-03 | 2.231 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 5.373506e-03 | 2.270 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 5.879205e-03 | 2.231 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 6.412465e-03 | 2.193 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 6.412465e-03 | 2.193 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 6.574526e-03 | 2.182 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 6.923429e-03 | 2.160 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 6.923429e-03 | 2.160 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 6.923429e-03 | 2.160 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 6.923429e-03 | 2.160 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.973657e-03 | 2.157 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 7.229578e-03 | 2.141 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.462629e-03 | 2.127 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 7.462629e-03 | 2.127 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 7.462629e-03 | 2.127 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 7.563126e-03 | 2.121 | 0 | 0 |
| Drug resistance of FLT3 mutants | R-HSA-9702506 | 1.154593e-02 | 1.938 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.154593e-02 | 1.938 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.154593e-02 | 1.938 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.154593e-02 | 1.938 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.154593e-02 | 1.938 | 0 | 0 |
| FLT3 mutants bind TKIs | R-HSA-9702509 | 1.154593e-02 | 1.938 | 0 | 0 |
| KW2449-resistant FLT3 mutants | R-HSA-9702569 | 1.154593e-02 | 1.938 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.154593e-02 | 1.938 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.154593e-02 | 1.938 | 0 | 0 |
| gilteritinib-resistant FLT3 mutants | R-HSA-9702590 | 1.154593e-02 | 1.938 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.154593e-02 | 1.938 | 0 | 0 |
| TLR3 deficiency - HSE | R-HSA-5602410 | 1.154593e-02 | 1.938 | 0 | 0 |
| midostaurin-resistant FLT3 mutants | R-HSA-9702600 | 1.154593e-02 | 1.938 | 0 | 0 |
| tamatinib-resistant FLT3 mutants | R-HSA-9703009 | 1.154593e-02 | 1.938 | 0 | 0 |
| tandutinib-resistant FLT3 mutants | R-HSA-9702636 | 1.154593e-02 | 1.938 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.154593e-02 | 1.938 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.154593e-02 | 1.938 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.154593e-02 | 1.938 | 0 | 0 |
| quizartinib-resistant FLT3 mutants | R-HSA-9702620 | 1.154593e-02 | 1.938 | 0 | 0 |
| ponatinib-resistant FLT3 mutants | R-HSA-9702614 | 1.154593e-02 | 1.938 | 0 | 0 |
| pexidartinib-resistant FLT3 mutants | R-HSA-9702605 | 1.154593e-02 | 1.938 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.154593e-02 | 1.938 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.154593e-02 | 1.938 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.154593e-02 | 1.938 | 0 | 0 |
| crenolanib-resistant FLT3 mutants | R-HSA-9702581 | 1.154593e-02 | 1.938 | 0 | 0 |
| semaxanib-resistant FLT3 mutants | R-HSA-9702577 | 1.154593e-02 | 1.938 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.154593e-02 | 1.938 | 0 | 0 |
| sunitinib-resistant FLT3 mutants | R-HSA-9702632 | 1.154593e-02 | 1.938 | 0 | 0 |
| sorafenib-resistant FLT3 mutants | R-HSA-9702624 | 1.154593e-02 | 1.938 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.154593e-02 | 1.938 | 0 | 0 |
| lestaurtinib-resistant FLT3 mutants | R-HSA-9702596 | 1.154593e-02 | 1.938 | 0 | 0 |
| linifanib-resistant FLT3 mutants | R-HSA-9702998 | 1.154593e-02 | 1.938 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 8.814099e-03 | 2.055 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.026630e-02 | 1.989 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 8.828154e-03 | 2.054 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.027393e-02 | 1.988 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 9.394380e-03 | 2.027 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 1.094508e-02 | 1.961 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.026630e-02 | 1.989 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.181192e-03 | 2.087 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 8.828154e-03 | 2.054 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.026630e-02 | 1.989 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.026630e-02 | 1.989 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.788577e-03 | 2.109 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 8.814099e-03 | 2.055 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.026630e-02 | 1.989 | 0 | 0 |
| M Phase | R-HSA-68886 | 7.916192e-03 | 2.101 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 9.113177e-03 | 2.040 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 9.743401e-03 | 2.011 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.097128e-03 | 2.092 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.168039e-02 | 1.933 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.181677e-02 | 1.928 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.237828e-02 | 1.907 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.241794e-02 | 1.906 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.284072e-02 | 1.891 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.314719e-02 | 1.881 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 1.333075e-02 | 1.875 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 1.333075e-02 | 1.875 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.358406e-02 | 1.867 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.418655e-02 | 1.848 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.466954e-02 | 1.834 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.509585e-02 | 1.821 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.520275e-02 | 1.818 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.520275e-02 | 1.818 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 1.520275e-02 | 1.818 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.520275e-02 | 1.818 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 1.520275e-02 | 1.818 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.645711e-02 | 1.784 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.693762e-02 | 1.771 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 1.703352e-02 | 1.769 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.703352e-02 | 1.769 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.743635e-02 | 1.759 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.771244e-02 | 1.752 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 1.895305e-02 | 1.722 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.895305e-02 | 1.722 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.895305e-02 | 1.722 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 1.895305e-02 | 1.722 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.295926e-02 | 1.639 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.295926e-02 | 1.639 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.295926e-02 | 1.639 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 2.295926e-02 | 1.639 | 0 | 0 |
| UNC93B1 deficiency - HSE | R-HSA-5602415 | 2.295926e-02 | 1.639 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 2.095907e-02 | 1.679 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.095907e-02 | 1.679 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 2.095907e-02 | 1.679 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 2.095907e-02 | 1.679 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.095907e-02 | 1.679 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 2.522170e-02 | 1.598 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.996613e-02 | 1.700 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.996613e-02 | 1.700 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.001542e-02 | 1.699 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.242088e-02 | 1.649 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.327351e-02 | 1.633 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.929005e-02 | 1.715 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 1.996613e-02 | 1.700 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 2.095907e-02 | 1.679 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.553029e-02 | 1.593 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.553029e-02 | 1.593 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.453935e-02 | 1.610 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.563351e-02 | 1.591 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.563351e-02 | 1.591 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.563351e-02 | 1.591 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.563351e-02 | 1.591 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.655117e-02 | 1.576 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.685998e-02 | 1.571 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.747396e-02 | 1.561 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.747396e-02 | 1.561 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.747396e-02 | 1.561 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.747396e-02 | 1.561 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 2.747396e-02 | 1.561 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.980402e-02 | 1.526 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.980402e-02 | 1.526 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.980402e-02 | 1.526 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 2.980402e-02 | 1.526 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 3.195158e-02 | 1.496 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 3.220980e-02 | 1.492 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 3.220980e-02 | 1.492 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 3.325095e-02 | 1.478 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.345479e-02 | 1.476 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 3.424150e-02 | 1.465 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 3.424150e-02 | 1.465 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 3.424150e-02 | 1.465 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 3.424150e-02 | 1.465 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.424150e-02 | 1.465 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 3.468927e-02 | 1.460 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.468927e-02 | 1.460 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 3.486568e-02 | 1.458 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 3.486568e-02 | 1.458 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 3.521376e-02 | 1.453 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 3.563679e-02 | 1.448 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 3.598598e-02 | 1.444 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 3.598598e-02 | 1.444 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 3.724042e-02 | 1.429 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 3.724042e-02 | 1.429 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 3.724042e-02 | 1.429 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.919648e-02 | 1.407 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.986129e-02 | 1.399 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.986129e-02 | 1.399 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.986129e-02 | 1.399 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.986129e-02 | 1.399 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 4.007597e-02 | 1.397 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.068590e-02 | 1.391 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 4.081193e-02 | 1.389 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 4.142496e-02 | 1.383 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 4.149066e-02 | 1.382 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.238344e-02 | 1.373 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 4.254995e-02 | 1.371 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 4.254995e-02 | 1.371 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 5.641868e-02 | 1.249 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 5.641868e-02 | 1.249 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 4.530449e-02 | 1.344 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.311347e-02 | 1.200 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 6.311347e-02 | 1.200 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 5.412529e-02 | 1.267 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 5.232509e-02 | 1.281 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 5.394500e-02 | 1.268 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 4.558543e-02 | 1.341 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 5.677144e-02 | 1.246 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 4.812306e-02 | 1.318 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 6.311347e-02 | 1.200 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 4.530449e-02 | 1.344 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 5.232509e-02 | 1.281 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 6.137802e-02 | 1.212 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 4.530449e-02 | 1.344 | 0 | 0 |
| Influenza Virus Induced Apoptosis | R-HSA-168277 | 4.539415e-02 | 1.343 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.641868e-02 | 1.249 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 5.694481e-02 | 1.245 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 5.694481e-02 | 1.245 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.232509e-02 | 1.281 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 4.609354e-02 | 1.336 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 4.723550e-02 | 1.326 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.062290e-02 | 1.296 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.062290e-02 | 1.296 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 6.312190e-02 | 1.200 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 6.312190e-02 | 1.200 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 6.320224e-02 | 1.199 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 4.604394e-02 | 1.337 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.891472e-02 | 1.311 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 6.051733e-02 | 1.218 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 6.059024e-02 | 1.218 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 5.694481e-02 | 1.245 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 6.380589e-02 | 1.195 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 5.232124e-02 | 1.281 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 6.463946e-02 | 1.190 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.622841e-02 | 1.335 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 5.694481e-02 | 1.245 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 6.609374e-02 | 1.180 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 6.609374e-02 | 1.180 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 6.627896e-02 | 1.179 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 6.627896e-02 | 1.179 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 6.627896e-02 | 1.179 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 6.726400e-02 | 1.172 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 6.731657e-02 | 1.172 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 6.731657e-02 | 1.172 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 6.731657e-02 | 1.172 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 6.731657e-02 | 1.172 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 6.731657e-02 | 1.172 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 6.731657e-02 | 1.172 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 6.731657e-02 | 1.172 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 6.756501e-02 | 1.170 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 6.866470e-02 | 1.163 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.924957e-02 | 1.160 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 6.949635e-02 | 1.158 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 6.949635e-02 | 1.158 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 6.971600e-02 | 1.157 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 7.126155e-02 | 1.147 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 7.126155e-02 | 1.147 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 7.126155e-02 | 1.147 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 7.276406e-02 | 1.138 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 7.516376e-02 | 1.124 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 7.536364e-02 | 1.123 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 7.608049e-02 | 1.119 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 7.608049e-02 | 1.119 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 7.608049e-02 | 1.119 | 0 | 0 |
| IRS activation | R-HSA-74713 | 7.808926e-02 | 1.107 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 7.808926e-02 | 1.107 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 7.808926e-02 | 1.107 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 7.833409e-02 | 1.106 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 7.956809e-02 | 1.099 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 8.285338e-02 | 1.082 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 8.285338e-02 | 1.082 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 8.285338e-02 | 1.082 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 8.387268e-02 | 1.076 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.630683e-02 | 1.064 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 8.827513e-02 | 1.054 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 8.873818e-02 | 1.052 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 8.873818e-02 | 1.052 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 8.873818e-02 | 1.052 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 8.873818e-02 | 1.052 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 8.873818e-02 | 1.052 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 8.873818e-02 | 1.052 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 8.873818e-02 | 1.052 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 9.926475e-02 | 1.003 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 9.926475e-02 | 1.003 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 1.096704e-01 | 0.960 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.096704e-01 | 0.960 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.096704e-01 | 0.960 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 1.199564e-01 | 0.921 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.199564e-01 | 0.921 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.199564e-01 | 0.921 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 1.401752e-01 | 0.853 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.401752e-01 | 0.853 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.401752e-01 | 0.853 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.401752e-01 | 0.853 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.501107e-01 | 0.824 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.501107e-01 | 0.824 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.501107e-01 | 0.824 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.599319e-01 | 0.796 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.599319e-01 | 0.796 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.696403e-01 | 0.770 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.696403e-01 | 0.770 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.696403e-01 | 0.770 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.696403e-01 | 0.770 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.696403e-01 | 0.770 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.696403e-01 | 0.770 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.696403e-01 | 0.770 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 9.691777e-02 | 1.014 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.625926e-01 | 0.789 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.707762e-01 | 0.768 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.116720e-01 | 0.952 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.141314e-01 | 0.943 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.241706e-01 | 0.906 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.478529e-01 | 0.830 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.615971e-01 | 0.792 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.599319e-01 | 0.796 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.792370e-01 | 0.747 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.401752e-01 | 0.853 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.041865e-01 | 0.982 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.044202e-01 | 0.981 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 9.334045e-02 | 1.030 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.115986e-01 | 0.952 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 1.115986e-01 | 0.952 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 9.505716e-02 | 1.022 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.504601e-01 | 0.823 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 9.926475e-02 | 1.003 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 1.096704e-01 | 0.960 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 1.464581e-01 | 0.834 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.267293e-01 | 0.897 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.067977e-01 | 0.971 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 1.068161e-01 | 0.971 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.401752e-01 | 0.853 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 1.401752e-01 | 0.853 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.501107e-01 | 0.824 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.501107e-01 | 0.824 | 0 | 0 |
| Conjugation of benzoate with glycine | R-HSA-177135 | 1.501107e-01 | 0.824 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.599319e-01 | 0.796 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.599319e-01 | 0.796 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 1.599319e-01 | 0.796 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.599319e-01 | 0.796 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 1.696403e-01 | 0.770 | 0 | 0 |
| Conjugation of salicylate with glycine | R-HSA-177128 | 1.696403e-01 | 0.770 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.792370e-01 | 0.747 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 1.041865e-01 | 0.982 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 1.041865e-01 | 0.982 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.166112e-01 | 0.933 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 8.980300e-02 | 1.047 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 1.696403e-01 | 0.770 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 1.268116e-01 | 0.897 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.786894e-01 | 0.748 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 1.191112e-01 | 0.924 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.096704e-01 | 0.960 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.199564e-01 | 0.921 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 1.301242e-01 | 0.886 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 1.401752e-01 | 0.853 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.696403e-01 | 0.770 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.504601e-01 | 0.823 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.792370e-01 | 0.747 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 1.385235e-01 | 0.858 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 1.293069e-01 | 0.888 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 1.096704e-01 | 0.960 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 1.599319e-01 | 0.796 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 1.792370e-01 | 0.747 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.153551e-01 | 0.938 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.306887e-01 | 0.884 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.790271e-01 | 0.747 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 1.643915e-01 | 0.784 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.424675e-01 | 0.846 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 9.277309e-02 | 1.033 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 1.499003e-01 | 0.824 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 1.150583e-01 | 0.939 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 1.096704e-01 | 0.960 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.301242e-01 | 0.886 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 1.501107e-01 | 0.824 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.696403e-01 | 0.770 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 1.696403e-01 | 0.770 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.041865e-01 | 0.982 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 1.464581e-01 | 0.834 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.505704e-01 | 0.822 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.696403e-01 | 0.770 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.945915e-02 | 1.002 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 1.599319e-01 | 0.796 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 9.926475e-02 | 1.003 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 1.501107e-01 | 0.824 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.031316e-01 | 0.987 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.229628e-01 | 0.910 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.229628e-01 | 0.910 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 1.005336e-01 | 0.998 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.268116e-01 | 0.897 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.501107e-01 | 0.824 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.691777e-02 | 1.014 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.792370e-01 | 0.747 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.666755e-01 | 0.778 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.501107e-01 | 0.824 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.199564e-01 | 0.921 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.319031e-01 | 0.880 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.615971e-01 | 0.792 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.615971e-01 | 0.792 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.640417e-01 | 0.785 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 1.620803e-01 | 0.790 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.700233e-01 | 0.769 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.306887e-01 | 0.884 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.487735e-01 | 0.827 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.371500e-01 | 0.863 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.230071e-01 | 0.910 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 1.873379e-01 | 0.727 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.873379e-01 | 0.727 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.873379e-01 | 0.727 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.887235e-01 | 0.724 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.887235e-01 | 0.724 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.887235e-01 | 0.724 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.887235e-01 | 0.724 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 1.901531e-01 | 0.721 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 1.919674e-01 | 0.717 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 1.957015e-01 | 0.708 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.957015e-01 | 0.708 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.981008e-01 | 0.703 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.981008e-01 | 0.703 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 1.981008e-01 | 0.703 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 1.981008e-01 | 0.703 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.981008e-01 | 0.703 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.981008e-01 | 0.703 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.981008e-01 | 0.703 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.981008e-01 | 0.703 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.981008e-01 | 0.703 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.996285e-01 | 0.700 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.999010e-01 | 0.699 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.999010e-01 | 0.699 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.073704e-01 | 0.683 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.073704e-01 | 0.683 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 2.073704e-01 | 0.683 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 2.073704e-01 | 0.683 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.073704e-01 | 0.683 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 2.073704e-01 | 0.683 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 2.073704e-01 | 0.683 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 2.073704e-01 | 0.683 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.125607e-01 | 0.673 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 2.165333e-01 | 0.664 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.165333e-01 | 0.664 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.165333e-01 | 0.664 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 2.167983e-01 | 0.664 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.169864e-01 | 0.664 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.190639e-01 | 0.659 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 2.210435e-01 | 0.656 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 2.212667e-01 | 0.655 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.255909e-01 | 0.647 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.295538e-01 | 0.639 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 2.295538e-01 | 0.639 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.295538e-01 | 0.639 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 2.337756e-01 | 0.631 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 2.338174e-01 | 0.631 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 2.338174e-01 | 0.631 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 2.338174e-01 | 0.631 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 2.345444e-01 | 0.630 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.345444e-01 | 0.630 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 2.345444e-01 | 0.630 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.423583e-01 | 0.616 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.433948e-01 | 0.614 | 0 | 0 |
| Conjugation of carboxylic acids | R-HSA-159424 | 2.433948e-01 | 0.614 | 0 | 0 |
| Amino Acid conjugation | R-HSA-156587 | 2.433948e-01 | 0.614 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.433948e-01 | 0.614 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 2.433948e-01 | 0.614 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.433948e-01 | 0.614 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 2.466342e-01 | 0.608 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.509128e-01 | 0.600 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.509128e-01 | 0.600 | 1 | 1 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 2.521435e-01 | 0.598 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.521435e-01 | 0.598 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.521435e-01 | 0.598 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.521435e-01 | 0.598 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.521435e-01 | 0.598 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 2.521435e-01 | 0.598 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.521435e-01 | 0.598 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.521435e-01 | 0.598 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.551936e-01 | 0.593 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.551936e-01 | 0.593 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 2.585850e-01 | 0.587 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 2.607916e-01 | 0.584 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 2.607916e-01 | 0.584 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.607916e-01 | 0.584 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.607916e-01 | 0.584 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 2.607916e-01 | 0.584 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 2.607916e-01 | 0.584 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.628737e-01 | 0.580 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 2.628737e-01 | 0.580 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.693401e-01 | 0.570 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.693401e-01 | 0.570 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 2.693401e-01 | 0.570 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 2.693401e-01 | 0.570 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.693401e-01 | 0.570 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.693401e-01 | 0.570 | 0 | 0 |
| Translation | R-HSA-72766 | 2.698212e-01 | 0.569 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 2.766087e-01 | 0.558 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.777904e-01 | 0.556 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 2.777904e-01 | 0.556 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 2.777904e-01 | 0.556 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 2.777904e-01 | 0.556 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 2.777904e-01 | 0.556 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 2.777904e-01 | 0.556 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 2.851691e-01 | 0.545 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.861434e-01 | 0.543 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.861434e-01 | 0.543 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 2.867010e-01 | 0.543 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.894460e-01 | 0.538 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.937200e-01 | 0.532 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.944003e-01 | 0.531 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 2.944003e-01 | 0.531 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.973571e-01 | 0.527 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.979905e-01 | 0.526 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.979905e-01 | 0.526 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 2.979905e-01 | 0.526 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 3.025622e-01 | 0.519 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 3.025622e-01 | 0.519 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 3.025622e-01 | 0.519 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 3.025622e-01 | 0.519 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.025622e-01 | 0.519 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.025622e-01 | 0.519 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 3.025622e-01 | 0.519 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 3.025622e-01 | 0.519 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 3.025622e-01 | 0.519 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.025622e-01 | 0.519 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.025622e-01 | 0.519 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.036629e-01 | 0.518 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 3.065193e-01 | 0.514 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 3.065193e-01 | 0.514 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.099751e-01 | 0.509 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 3.106302e-01 | 0.508 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 3.106302e-01 | 0.508 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 3.106302e-01 | 0.508 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.106302e-01 | 0.508 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 3.162918e-01 | 0.500 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 3.186054e-01 | 0.497 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 3.186054e-01 | 0.497 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 3.186054e-01 | 0.497 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 3.186054e-01 | 0.497 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 3.186054e-01 | 0.497 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.192750e-01 | 0.496 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.192750e-01 | 0.496 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 3.194513e-01 | 0.496 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.256825e-01 | 0.487 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.257714e-01 | 0.487 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.264888e-01 | 0.486 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.264888e-01 | 0.486 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 3.264888e-01 | 0.486 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 3.264888e-01 | 0.486 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 3.282977e-01 | 0.484 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 3.319750e-01 | 0.479 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 3.342815e-01 | 0.476 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.342815e-01 | 0.476 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.342815e-01 | 0.476 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.352513e-01 | 0.475 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 3.358023e-01 | 0.474 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 3.361510e-01 | 0.473 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 3.404053e-01 | 0.468 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 3.413914e-01 | 0.467 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.415687e-01 | 0.467 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.419845e-01 | 0.466 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.478820e-01 | 0.459 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.495988e-01 | 0.456 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.495988e-01 | 0.456 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 3.495988e-01 | 0.456 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 3.495988e-01 | 0.456 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 3.495988e-01 | 0.456 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 3.529884e-01 | 0.452 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 3.529884e-01 | 0.452 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 3.541897e-01 | 0.451 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 3.571255e-01 | 0.447 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 3.571255e-01 | 0.447 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 3.571255e-01 | 0.447 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.571255e-01 | 0.447 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 3.645655e-01 | 0.438 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.645655e-01 | 0.438 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.645655e-01 | 0.438 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.645655e-01 | 0.438 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.645655e-01 | 0.438 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.645655e-01 | 0.438 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 3.645655e-01 | 0.438 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.645655e-01 | 0.438 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 3.696344e-01 | 0.432 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 3.719199e-01 | 0.430 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.719199e-01 | 0.430 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.719199e-01 | 0.430 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 3.719199e-01 | 0.430 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 3.719199e-01 | 0.430 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 3.719199e-01 | 0.430 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 3.778951e-01 | 0.423 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 3.791896e-01 | 0.421 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 3.791896e-01 | 0.421 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.791896e-01 | 0.421 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.791896e-01 | 0.421 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.791896e-01 | 0.421 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.791896e-01 | 0.421 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 3.791896e-01 | 0.421 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 3.791896e-01 | 0.421 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 3.791896e-01 | 0.421 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.807166e-01 | 0.419 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.855911e-01 | 0.414 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.861110e-01 | 0.413 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.863757e-01 | 0.413 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 3.863757e-01 | 0.413 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.863757e-01 | 0.413 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 3.863757e-01 | 0.413 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 3.863757e-01 | 0.413 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 3.863757e-01 | 0.413 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 3.918339e-01 | 0.407 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 3.934789e-01 | 0.405 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.934789e-01 | 0.405 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.934789e-01 | 0.405 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.934789e-01 | 0.405 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.934789e-01 | 0.405 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.942798e-01 | 0.404 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 3.942798e-01 | 0.404 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 3.983458e-01 | 0.400 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.983458e-01 | 0.400 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 4.005004e-01 | 0.397 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 4.005004e-01 | 0.397 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 4.005004e-01 | 0.397 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 4.005004e-01 | 0.397 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 4.005004e-01 | 0.397 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.005004e-01 | 0.397 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 4.011683e-01 | 0.397 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 4.074411e-01 | 0.390 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 4.090744e-01 | 0.388 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 4.143018e-01 | 0.383 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.143018e-01 | 0.383 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 4.143018e-01 | 0.383 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 4.143018e-01 | 0.383 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.143018e-01 | 0.383 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.144817e-01 | 0.382 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.144817e-01 | 0.382 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 4.210835e-01 | 0.376 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 4.210835e-01 | 0.376 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.210835e-01 | 0.376 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 4.210835e-01 | 0.376 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 4.210835e-01 | 0.376 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 4.210835e-01 | 0.376 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 4.210835e-01 | 0.376 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.210835e-01 | 0.376 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 4.210835e-01 | 0.376 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 4.210835e-01 | 0.376 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 4.224694e-01 | 0.374 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.224694e-01 | 0.374 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 4.258557e-01 | 0.371 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.277871e-01 | 0.369 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 4.277871e-01 | 0.369 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 4.277871e-01 | 0.369 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.277871e-01 | 0.369 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.304011e-01 | 0.366 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.344134e-01 | 0.362 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.344134e-01 | 0.362 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.344134e-01 | 0.362 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 4.344134e-01 | 0.362 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 4.382752e-01 | 0.358 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 4.409635e-01 | 0.356 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 4.409635e-01 | 0.356 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 4.409635e-01 | 0.356 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.455638e-01 | 0.351 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.474381e-01 | 0.349 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 4.474381e-01 | 0.349 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 4.538381e-01 | 0.343 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.538381e-01 | 0.343 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 4.538381e-01 | 0.343 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.538381e-01 | 0.343 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.576989e-01 | 0.339 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.576989e-01 | 0.339 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.601643e-01 | 0.337 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.601643e-01 | 0.337 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.601643e-01 | 0.337 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.601643e-01 | 0.337 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.601643e-01 | 0.337 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.601643e-01 | 0.337 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 4.615374e-01 | 0.336 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.653601e-01 | 0.332 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 4.659210e-01 | 0.332 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.664177e-01 | 0.331 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.664177e-01 | 0.331 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 4.664177e-01 | 0.331 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.664177e-01 | 0.331 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.664177e-01 | 0.331 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 4.681622e-01 | 0.330 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.691668e-01 | 0.329 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.691668e-01 | 0.329 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.725990e-01 | 0.326 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 4.767319e-01 | 0.322 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 4.787091e-01 | 0.320 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 4.787091e-01 | 0.320 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.842316e-01 | 0.315 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.847488e-01 | 0.314 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.847488e-01 | 0.314 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.847488e-01 | 0.314 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.847488e-01 | 0.314 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 4.907188e-01 | 0.309 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 4.966201e-01 | 0.304 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.966201e-01 | 0.304 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.966201e-01 | 0.304 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.966201e-01 | 0.304 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 5.024533e-01 | 0.299 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 5.024533e-01 | 0.299 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 5.024533e-01 | 0.299 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 5.024533e-01 | 0.299 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.024533e-01 | 0.299 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 5.057982e-01 | 0.296 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.063288e-01 | 0.296 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 5.082193e-01 | 0.294 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.082193e-01 | 0.294 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 5.082193e-01 | 0.294 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 5.082193e-01 | 0.294 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 5.099520e-01 | 0.292 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 5.139188e-01 | 0.289 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 5.139188e-01 | 0.289 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 5.195527e-01 | 0.284 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 5.195527e-01 | 0.284 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 5.195527e-01 | 0.284 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 5.251215e-01 | 0.280 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 5.251215e-01 | 0.280 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.251215e-01 | 0.280 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 5.306262e-01 | 0.275 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 5.348245e-01 | 0.272 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 5.360674e-01 | 0.271 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 5.360674e-01 | 0.271 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.414459e-01 | 0.266 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 5.414459e-01 | 0.266 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 5.467623e-01 | 0.262 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 5.467623e-01 | 0.262 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 5.467623e-01 | 0.262 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 5.467623e-01 | 0.262 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 5.467623e-01 | 0.262 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 5.467623e-01 | 0.262 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 5.467623e-01 | 0.262 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 5.467623e-01 | 0.262 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 5.467623e-01 | 0.262 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 5.467623e-01 | 0.262 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 5.520174e-01 | 0.258 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.520174e-01 | 0.258 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 5.520174e-01 | 0.258 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.554499e-01 | 0.255 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 5.572119e-01 | 0.254 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.572119e-01 | 0.254 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.572119e-01 | 0.254 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 5.623465e-01 | 0.250 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 5.623465e-01 | 0.250 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.623465e-01 | 0.250 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.674219e-01 | 0.246 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 5.721401e-01 | 0.242 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 5.724387e-01 | 0.242 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.724387e-01 | 0.242 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 5.751069e-01 | 0.240 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.822994e-01 | 0.235 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 5.822994e-01 | 0.235 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 5.836446e-01 | 0.234 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.871445e-01 | 0.231 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 5.915657e-01 | 0.228 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 5.966678e-01 | 0.224 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 5.966678e-01 | 0.224 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 5.966678e-01 | 0.224 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.966678e-01 | 0.224 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.966678e-01 | 0.224 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 5.966678e-01 | 0.224 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 6.013472e-01 | 0.221 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.013472e-01 | 0.221 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.013472e-01 | 0.221 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 6.013472e-01 | 0.221 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 6.013472e-01 | 0.221 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 6.041494e-01 | 0.219 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 6.041494e-01 | 0.219 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.059726e-01 | 0.218 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 6.059726e-01 | 0.218 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 6.059726e-01 | 0.218 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 6.105446e-01 | 0.214 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 6.105446e-01 | 0.214 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 6.133946e-01 | 0.212 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 6.150638e-01 | 0.211 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 6.195309e-01 | 0.208 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 6.195309e-01 | 0.208 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 6.195309e-01 | 0.208 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 6.228540e-01 | 0.206 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 6.239464e-01 | 0.205 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 6.281890e-01 | 0.202 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.326250e-01 | 0.199 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.326250e-01 | 0.199 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 6.326250e-01 | 0.199 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 6.326250e-01 | 0.199 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 6.326250e-01 | 0.199 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 6.326250e-01 | 0.199 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 6.411045e-01 | 0.193 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 6.411045e-01 | 0.193 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 6.452709e-01 | 0.190 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 6.457167e-01 | 0.190 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.487311e-01 | 0.188 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 6.515579e-01 | 0.186 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 6.534599e-01 | 0.185 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 6.574837e-01 | 0.182 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.614609e-01 | 0.179 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.692782e-01 | 0.174 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 6.692782e-01 | 0.174 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 6.814723e-01 | 0.167 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 6.987920e-01 | 0.156 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 6.987920e-01 | 0.156 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 7.049345e-01 | 0.152 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.057515e-01 | 0.151 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 7.091711e-01 | 0.149 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 7.125511e-01 | 0.147 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 7.158920e-01 | 0.145 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 7.191943e-01 | 0.143 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 7.191943e-01 | 0.143 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 7.191943e-01 | 0.143 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 7.191943e-01 | 0.143 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 7.224585e-01 | 0.141 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 7.224585e-01 | 0.141 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 7.224585e-01 | 0.141 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 7.256849e-01 | 0.139 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 7.288739e-01 | 0.137 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 7.288739e-01 | 0.137 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 7.320261e-01 | 0.135 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 7.351419e-01 | 0.134 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 7.382216e-01 | 0.132 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 7.394878e-01 | 0.131 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 7.412657e-01 | 0.130 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.501883e-01 | 0.125 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 7.525127e-01 | 0.123 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.530940e-01 | 0.123 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 7.559660e-01 | 0.121 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 7.559660e-01 | 0.121 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.559660e-01 | 0.121 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 7.588048e-01 | 0.120 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 7.649759e-01 | 0.116 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.671256e-01 | 0.115 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 7.698353e-01 | 0.114 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 7.777776e-01 | 0.109 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 7.777776e-01 | 0.109 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 7.854472e-01 | 0.105 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.879447e-01 | 0.104 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 7.928535e-01 | 0.101 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.976491e-01 | 0.098 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 8.009236e-01 | 0.096 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 8.044110e-01 | 0.095 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 8.056453e-01 | 0.094 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 8.069117e-01 | 0.093 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 8.091606e-01 | 0.092 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 8.091606e-01 | 0.092 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 8.200206e-01 | 0.086 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 8.200206e-01 | 0.086 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 8.200206e-01 | 0.086 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 8.204038e-01 | 0.086 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.221176e-01 | 0.085 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 8.238484e-01 | 0.084 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 8.241904e-01 | 0.084 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 8.322439e-01 | 0.080 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 8.361320e-01 | 0.078 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.454645e-01 | 0.073 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.490477e-01 | 0.071 | 0 | 0 |
| S Phase | R-HSA-69242 | 8.559681e-01 | 0.068 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.576483e-01 | 0.067 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.593090e-01 | 0.066 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.609504e-01 | 0.065 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.625728e-01 | 0.064 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 8.625728e-01 | 0.064 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 8.627081e-01 | 0.064 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 8.641763e-01 | 0.063 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 8.657613e-01 | 0.063 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 8.704066e-01 | 0.060 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 8.762256e-01 | 0.057 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 8.884970e-01 | 0.051 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.900567e-01 | 0.051 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 8.938652e-01 | 0.049 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 8.938652e-01 | 0.049 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 9.095440e-01 | 0.041 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.103972e-01 | 0.041 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.151172e-01 | 0.039 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.161629e-01 | 0.038 | 1 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.389612e-01 | 0.027 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.403836e-01 | 0.027 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.412697e-01 | 0.026 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.531224e-01 | 0.021 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.561331e-01 | 0.019 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.562488e-01 | 0.019 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.603726e-01 | 0.018 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.741881e-01 | 0.011 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.878025e-01 | 0.005 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.917607e-01 | 0.004 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.921944e-01 | 0.003 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.929493e-01 | 0.003 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 9.997845e-01 | 0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 3.874678e-14 | 13.412 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 1.075806e-13 | 12.968 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.075806e-13 | 12.968 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.018385e-13 | 12.695 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 4.855005e-13 | 12.314 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 6.402656e-13 | 12.194 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.090239e-12 | 11.962 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.090239e-12 | 11.962 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.808442e-12 | 11.743 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 2.308154e-12 | 11.637 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 2.308154e-12 | 11.637 | 0 | 0 |
| Depurination | R-HSA-73927 | 2.929101e-12 | 11.533 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 3.571698e-12 | 11.447 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.642065e-12 | 11.333 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 4.642065e-12 | 11.333 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 5.799805e-12 | 11.237 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 5.799805e-12 | 11.237 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 8.926193e-12 | 11.049 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 8.926193e-12 | 11.049 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.099987e-11 | 10.959 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.649647e-11 | 10.783 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.649647e-11 | 10.783 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.870137e-11 | 10.728 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 2.008205e-11 | 10.697 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.942968e-11 | 10.531 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.992229e-11 | 10.524 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 5.086864e-11 | 10.294 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.065437e-11 | 10.217 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 7.210188e-11 | 10.142 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 7.801926e-11 | 10.108 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 8.545697e-11 | 10.068 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.009963e-10 | 9.996 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.141458e-10 | 9.943 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.640230e-10 | 9.785 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.918072e-10 | 9.717 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.237490e-10 | 9.650 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.237490e-10 | 9.650 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.783591e-10 | 9.555 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 3.023313e-10 | 9.520 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 3.023313e-10 | 9.520 | 0 | 0 |
| M Phase | R-HSA-68886 | 3.279749e-10 | 9.484 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.749444e-10 | 9.426 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 4.230817e-10 | 9.374 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.375729e-10 | 9.270 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 5.152396e-10 | 9.288 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 5.728433e-10 | 9.242 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 6.175660e-10 | 9.209 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.766336e-10 | 9.170 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 6.920304e-10 | 9.160 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 7.080764e-10 | 9.150 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.490773e-10 | 9.071 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 9.255792e-10 | 9.034 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 9.255792e-10 | 9.034 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.055339e-09 | 8.977 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.055339e-09 | 8.977 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.045842e-09 | 8.981 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 1.317758e-09 | 8.880 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.548141e-09 | 8.810 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.982318e-09 | 8.703 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.225639e-09 | 8.653 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 2.522477e-09 | 8.598 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.904212e-09 | 8.537 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 3.043319e-09 | 8.517 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 3.185765e-09 | 8.497 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.190782e-09 | 8.496 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 3.580960e-09 | 8.446 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 3.580960e-09 | 8.446 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 4.013274e-09 | 8.397 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 7.750065e-09 | 8.111 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.120785e-08 | 7.950 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 1.169640e-08 | 7.932 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.204785e-08 | 7.919 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.651155e-08 | 7.782 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.919711e-08 | 7.717 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.995489e-08 | 7.700 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.544000e-08 | 7.594 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 3.052098e-08 | 7.515 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.404247e-08 | 7.468 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 3.994946e-08 | 7.398 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.994946e-08 | 7.398 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 4.006822e-08 | 7.397 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 4.033439e-08 | 7.394 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 4.383180e-08 | 7.358 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 4.821456e-08 | 7.317 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 5.188665e-08 | 7.285 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 5.188665e-08 | 7.285 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.902431e-08 | 7.229 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 7.034913e-08 | 7.153 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 7.848545e-08 | 7.105 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 9.054727e-08 | 7.043 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.006776e-07 | 6.997 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 1.089282e-07 | 6.963 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.345673e-07 | 6.871 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.398324e-07 | 6.854 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.496766e-07 | 6.825 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.496766e-07 | 6.825 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.496766e-07 | 6.825 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.535108e-07 | 6.814 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.987174e-07 | 6.702 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.159738e-07 | 6.666 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 2.648151e-07 | 6.577 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.904402e-07 | 6.537 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 3.145450e-07 | 6.502 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 3.221382e-07 | 6.492 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 3.314403e-07 | 6.480 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 3.314403e-07 | 6.480 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 3.314403e-07 | 6.480 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.881147e-07 | 6.411 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 3.974237e-07 | 6.401 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 6.502532e-07 | 6.187 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 7.904389e-07 | 6.102 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 9.214504e-07 | 6.036 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 9.214504e-07 | 6.036 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 9.061531e-07 | 6.043 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.015120e-06 | 5.993 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.015120e-06 | 5.993 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 9.919549e-07 | 6.004 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.043428e-06 | 5.982 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.438931e-06 | 5.842 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.575001e-06 | 5.803 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.886691e-06 | 5.724 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.046614e-06 | 5.689 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 2.194872e-06 | 5.659 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.225910e-06 | 5.652 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.397996e-06 | 5.620 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.613285e-06 | 5.583 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.053903e-06 | 5.515 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 3.165915e-06 | 5.500 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 3.319448e-06 | 5.479 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 4.063349e-06 | 5.391 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 4.116993e-06 | 5.385 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.194133e-06 | 5.377 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 5.346632e-06 | 5.272 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 4.868859e-06 | 5.313 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 5.463177e-06 | 5.263 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 7.900279e-06 | 5.102 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 8.737284e-06 | 5.059 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 9.373369e-06 | 5.028 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.087059e-05 | 4.964 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.231931e-05 | 4.909 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.264465e-05 | 4.898 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.346571e-05 | 4.871 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.486409e-05 | 4.828 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 1.817920e-05 | 4.740 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.968849e-05 | 4.706 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 2.069299e-05 | 4.684 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.069299e-05 | 4.684 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.544091e-05 | 4.594 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 2.823743e-05 | 4.549 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.823743e-05 | 4.549 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 3.421640e-05 | 4.466 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.439260e-05 | 4.464 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.122354e-05 | 4.385 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 4.333472e-05 | 4.363 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 4.464375e-05 | 4.350 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 4.874777e-05 | 4.312 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 7.808680e-05 | 4.107 | 0 | 0 |
| Kinesins | R-HSA-983189 | 9.024547e-05 | 4.045 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.289432e-05 | 4.032 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 8.163797e-05 | 4.088 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 9.322363e-05 | 4.030 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 8.413936e-05 | 4.075 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 9.329861e-05 | 4.030 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.093379e-04 | 3.961 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.093379e-04 | 3.961 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.111417e-04 | 3.954 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.139710e-04 | 3.943 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.139710e-04 | 3.943 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.139710e-04 | 3.943 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 1.251372e-04 | 3.903 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.266578e-04 | 3.897 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.384082e-04 | 3.859 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.424007e-04 | 3.846 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.839143e-04 | 3.735 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.991540e-04 | 3.701 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 2.020032e-04 | 3.695 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 2.274164e-04 | 3.643 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.307275e-04 | 3.637 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.307275e-04 | 3.637 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.625752e-04 | 3.581 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.661918e-04 | 3.575 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 3.339384e-04 | 3.476 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.789732e-04 | 3.421 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 3.886913e-04 | 3.410 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 4.303829e-04 | 3.366 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 4.321511e-04 | 3.364 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 4.457307e-04 | 3.351 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.510477e-04 | 3.346 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.553989e-04 | 3.342 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 4.769597e-04 | 3.322 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 4.912187e-04 | 3.309 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 5.212350e-04 | 3.283 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.358327e-04 | 3.271 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.359193e-04 | 3.271 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.380805e-04 | 3.269 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 5.627855e-04 | 3.250 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.974262e-04 | 3.224 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 8.421374e-04 | 3.075 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 8.421374e-04 | 3.075 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 8.421374e-04 | 3.075 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 8.421374e-04 | 3.075 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 6.598542e-04 | 3.181 | 0 | 0 |
| Protein folding | R-HSA-391251 | 7.694220e-04 | 3.114 | 0 | 0 |
| Immune System | R-HSA-168256 | 7.991678e-04 | 3.097 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 9.827045e-04 | 3.008 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.011413e-03 | 2.995 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.039338e-03 | 2.983 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.102536e-03 | 2.958 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.135535e-03 | 2.945 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.149407e-03 | 2.940 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.183899e-03 | 2.927 | 0 | 0 |
| TRKA activation by NGF | R-HSA-187042 | 1.306861e-03 | 2.884 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 1.466149e-03 | 2.834 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.466588e-03 | 2.834 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 1.588660e-03 | 2.799 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.768047e-03 | 2.753 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 1.810894e-03 | 2.742 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.825046e-03 | 2.739 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.869048e-03 | 2.728 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.881088e-03 | 2.726 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.897135e-03 | 2.722 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 2.280984e-03 | 2.642 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 2.286798e-03 | 2.641 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 2.399582e-03 | 2.620 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 2.410833e-03 | 2.618 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 2.449458e-03 | 2.611 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.793983e-03 | 2.554 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 2.978839e-03 | 2.526 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 3.127020e-03 | 2.505 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 3.211277e-03 | 2.493 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.239607e-03 | 2.490 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.277652e-03 | 2.484 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 3.444952e-03 | 2.463 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.579503e-03 | 2.446 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.670709e-03 | 2.435 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 4.120064e-03 | 2.385 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.371626e-03 | 2.359 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.371626e-03 | 2.359 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 4.406998e-03 | 2.356 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.998003e-03 | 2.301 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 5.051932e-03 | 2.297 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 5.051932e-03 | 2.297 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 5.870255e-03 | 2.231 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 6.051552e-03 | 2.218 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 6.071331e-03 | 2.217 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 6.619953e-03 | 2.179 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.037893e-02 | 1.984 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.037893e-02 | 1.984 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.037893e-02 | 1.984 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.037893e-02 | 1.984 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.037893e-02 | 1.984 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.037893e-02 | 1.984 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 8.774304e-03 | 2.057 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 8.882132e-03 | 2.051 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 8.882132e-03 | 2.051 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.024548e-02 | 1.989 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 8.365169e-03 | 2.078 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.176366e-03 | 2.144 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 7.637179e-03 | 2.117 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.048146e-02 | 1.980 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.060815e-02 | 1.974 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.081340e-02 | 1.966 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.097719e-02 | 1.960 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 1.098677e-02 | 1.959 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.159159e-02 | 1.936 | 1 | 1 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.220948e-02 | 1.913 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.220948e-02 | 1.913 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.241597e-02 | 1.906 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.241597e-02 | 1.906 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.350380e-02 | 1.870 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.415788e-02 | 1.849 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.427663e-02 | 1.845 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.495413e-02 | 1.825 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.677465e-02 | 1.775 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.715628e-02 | 1.766 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.721033e-02 | 1.764 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.833708e-02 | 1.737 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.888163e-02 | 1.724 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 1.935548e-02 | 1.713 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.943377e-02 | 1.711 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.056030e-02 | 1.687 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.065076e-02 | 1.685 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 2.067631e-02 | 1.685 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 2.135202e-02 | 1.671 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.204454e-02 | 1.657 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 2.221117e-02 | 1.653 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.254027e-02 | 1.647 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.254027e-02 | 1.647 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.275066e-02 | 1.643 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 2.398702e-02 | 1.620 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.447036e-02 | 1.611 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.447036e-02 | 1.611 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.447036e-02 | 1.611 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.495120e-02 | 1.603 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 2.495120e-02 | 1.603 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.571228e-02 | 1.590 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 2.571228e-02 | 1.590 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 2.571228e-02 | 1.590 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 2.673614e-02 | 1.573 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 2.753891e-02 | 1.560 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.852424e-02 | 1.545 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.852424e-02 | 1.545 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.852424e-02 | 1.545 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 2.852424e-02 | 1.545 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.972645e-02 | 1.527 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.983264e-02 | 1.525 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 3.057130e-02 | 1.515 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 3.064497e-02 | 1.514 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 3.064497e-02 | 1.514 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.081661e-02 | 1.511 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.081661e-02 | 1.511 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.228505e-02 | 1.491 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.230327e-02 | 1.491 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.282624e-02 | 1.484 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 3.282624e-02 | 1.484 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.282624e-02 | 1.484 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.319045e-02 | 1.479 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 3.370226e-02 | 1.472 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.506656e-02 | 1.455 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.506656e-02 | 1.455 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 3.576721e-02 | 1.447 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.589976e-02 | 1.445 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 3.688087e-02 | 1.433 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.736450e-02 | 1.428 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.783899e-02 | 1.422 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 3.801308e-02 | 1.420 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.979791e-02 | 1.400 | 0 | 0 |
| NTF3 activates NTRK3 signaling | R-HSA-9034013 | 4.087756e-02 | 1.389 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 4.087756e-02 | 1.389 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 4.087756e-02 | 1.389 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.181377e-02 | 1.379 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.181377e-02 | 1.379 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 4.181377e-02 | 1.379 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 4.212756e-02 | 1.375 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 4.458991e-02 | 1.351 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.458991e-02 | 1.351 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 4.710253e-02 | 1.327 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 4.710433e-02 | 1.327 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 4.931750e-02 | 1.307 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 4.979381e-02 | 1.303 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 5.083468e-02 | 1.294 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 5.083468e-02 | 1.294 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 5.083468e-02 | 1.294 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 5.083468e-02 | 1.294 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 5.083468e-02 | 1.294 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 5.083468e-02 | 1.294 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 5.083468e-02 | 1.294 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 6.068904e-02 | 1.217 | 0 | 0 |
| IRS activation | R-HSA-74713 | 7.044170e-02 | 1.152 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 8.009369e-02 | 1.096 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.009369e-02 | 1.096 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 8.009369e-02 | 1.096 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 8.009369e-02 | 1.096 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 8.009369e-02 | 1.096 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 8.964605e-02 | 1.047 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 9.909980e-02 | 1.004 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 9.909980e-02 | 1.004 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.765633e-02 | 1.239 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 6.430788e-02 | 1.192 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 8.317887e-02 | 1.080 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 8.317887e-02 | 1.080 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 8.317887e-02 | 1.080 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 9.909980e-02 | 1.004 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.660582e-02 | 1.015 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 8.009369e-02 | 1.096 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 8.964605e-02 | 1.047 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 9.021277e-02 | 1.045 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 5.765633e-02 | 1.239 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.186431e-02 | 1.143 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.083468e-02 | 1.294 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 9.909980e-02 | 1.004 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 5.228405e-02 | 1.282 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.482963e-02 | 1.126 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.393166e-02 | 1.027 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.087484e-02 | 1.092 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 6.321112e-02 | 1.199 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 7.044170e-02 | 1.152 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.425695e-02 | 1.074 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 5.765633e-02 | 1.239 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.677868e-02 | 1.014 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.677868e-02 | 1.014 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 6.068904e-02 | 1.217 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 8.009369e-02 | 1.096 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 6.321112e-02 | 1.199 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 8.009369e-02 | 1.096 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 8.964605e-02 | 1.047 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 9.909980e-02 | 1.004 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.706553e-02 | 1.060 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 9.660582e-02 | 1.015 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 6.041153e-02 | 1.219 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 5.494676e-02 | 1.260 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 7.482963e-02 | 1.126 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.984963e-02 | 1.001 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 6.893869e-02 | 1.162 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 8.433407e-02 | 1.074 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.402875e-02 | 1.027 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 8.797692e-02 | 1.056 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.395254e-02 | 1.076 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.002119e-01 | 0.999 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.022879e-01 | 0.990 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 1.031236e-01 | 0.987 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.064269e-01 | 0.973 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 1.065737e-01 | 0.972 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.067782e-01 | 0.972 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 1.084560e-01 | 0.965 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.084560e-01 | 0.965 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 1.084560e-01 | 0.965 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.087427e-01 | 0.964 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 1.123174e-01 | 0.950 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 1.135349e-01 | 0.945 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 1.135349e-01 | 0.945 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.177155e-01 | 0.929 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 1.177155e-01 | 0.929 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.177155e-01 | 0.929 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.177155e-01 | 0.929 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.177155e-01 | 0.929 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.199134e-01 | 0.921 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.204764e-01 | 0.919 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 1.221087e-01 | 0.913 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 1.233489e-01 | 0.909 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.240148e-01 | 0.907 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.268082e-01 | 0.897 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.268795e-01 | 0.897 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 1.268795e-01 | 0.897 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.268795e-01 | 0.897 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.268795e-01 | 0.897 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.268795e-01 | 0.897 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 1.268795e-01 | 0.897 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.268795e-01 | 0.897 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 1.302904e-01 | 0.885 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 1.302904e-01 | 0.885 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.343634e-01 | 0.872 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 1.359488e-01 | 0.867 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.359488e-01 | 0.867 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.359488e-01 | 0.867 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 1.359488e-01 | 0.867 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.359488e-01 | 0.867 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.373201e-01 | 0.862 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.444317e-01 | 0.840 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.444317e-01 | 0.840 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.444317e-01 | 0.840 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 1.444317e-01 | 0.840 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.449245e-01 | 0.839 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.480161e-01 | 0.830 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 1.480161e-01 | 0.830 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 1.480497e-01 | 0.830 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.499402e-01 | 0.824 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.516187e-01 | 0.819 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 1.516187e-01 | 0.819 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 1.529469e-01 | 0.815 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.538075e-01 | 0.813 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.538075e-01 | 0.813 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 1.538075e-01 | 0.813 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 1.538075e-01 | 0.813 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.538075e-01 | 0.813 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 1.538075e-01 | 0.813 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 1.538075e-01 | 0.813 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.538075e-01 | 0.813 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 1.624159e-01 | 0.789 | 1 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.625988e-01 | 0.789 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 1.625988e-01 | 0.789 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.661948e-01 | 0.779 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 1.661948e-01 | 0.779 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.661948e-01 | 0.779 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 1.712992e-01 | 0.766 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 1.712992e-01 | 0.766 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.712992e-01 | 0.766 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 1.712992e-01 | 0.766 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.752723e-01 | 0.756 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.755882e-01 | 0.756 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.772813e-01 | 0.751 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.799098e-01 | 0.745 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.799098e-01 | 0.745 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.799098e-01 | 0.745 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 1.799098e-01 | 0.745 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 1.799098e-01 | 0.745 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 1.799098e-01 | 0.745 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.799098e-01 | 0.745 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.807429e-01 | 0.743 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 1.833356e-01 | 0.737 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 1.847355e-01 | 0.733 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.848315e-01 | 0.733 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 1.884315e-01 | 0.725 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 1.884315e-01 | 0.725 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.884315e-01 | 0.725 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 1.898273e-01 | 0.722 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 1.968651e-01 | 0.706 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 1.968651e-01 | 0.706 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 1.968651e-01 | 0.706 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 1.968651e-01 | 0.706 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 1.968651e-01 | 0.706 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.968651e-01 | 0.706 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.052116e-01 | 0.688 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.052116e-01 | 0.688 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 2.052116e-01 | 0.688 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 2.052116e-01 | 0.688 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 2.052116e-01 | 0.688 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 2.052116e-01 | 0.688 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.052116e-01 | 0.688 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.073455e-01 | 0.683 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.134719e-01 | 0.671 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.134719e-01 | 0.671 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 2.134719e-01 | 0.671 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 2.149487e-01 | 0.668 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.187602e-01 | 0.660 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.216468e-01 | 0.654 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.216468e-01 | 0.654 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.216468e-01 | 0.654 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.216468e-01 | 0.654 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.264003e-01 | 0.645 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 2.268688e-01 | 0.644 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 2.297373e-01 | 0.639 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.297373e-01 | 0.639 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.340598e-01 | 0.631 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.342463e-01 | 0.630 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.343749e-01 | 0.630 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.369975e-01 | 0.625 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 2.377442e-01 | 0.624 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.377442e-01 | 0.624 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.452846e-01 | 0.610 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.456683e-01 | 0.610 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 2.456683e-01 | 0.610 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.456683e-01 | 0.610 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 2.456683e-01 | 0.610 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 2.456683e-01 | 0.610 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.494208e-01 | 0.603 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.508351e-01 | 0.601 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.535105e-01 | 0.596 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.535105e-01 | 0.596 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 2.571147e-01 | 0.590 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 2.597804e-01 | 0.585 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.605444e-01 | 0.584 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 2.612717e-01 | 0.583 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.612717e-01 | 0.583 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.612717e-01 | 0.583 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.619912e-01 | 0.582 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.648129e-01 | 0.577 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 2.689527e-01 | 0.570 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 2.689527e-01 | 0.570 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 2.689527e-01 | 0.570 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.689527e-01 | 0.570 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.689527e-01 | 0.570 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.689527e-01 | 0.570 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.689527e-01 | 0.570 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 2.763604e-01 | 0.559 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 2.765542e-01 | 0.558 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 2.765542e-01 | 0.558 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 2.765542e-01 | 0.558 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 2.765542e-01 | 0.558 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 2.765542e-01 | 0.558 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.802080e-01 | 0.553 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 2.840772e-01 | 0.547 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 2.840772e-01 | 0.547 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.840772e-01 | 0.547 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 2.915225e-01 | 0.535 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 2.915225e-01 | 0.535 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.915225e-01 | 0.535 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 2.915225e-01 | 0.535 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.915225e-01 | 0.535 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 2.917407e-01 | 0.535 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 2.955803e-01 | 0.529 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 2.988907e-01 | 0.524 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 2.988907e-01 | 0.524 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.061828e-01 | 0.514 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 3.061828e-01 | 0.514 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 3.061828e-01 | 0.514 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 3.133995e-01 | 0.504 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 3.184846e-01 | 0.497 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.205415e-01 | 0.494 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 3.205415e-01 | 0.494 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 3.205415e-01 | 0.494 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 3.241658e-01 | 0.489 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 3.241658e-01 | 0.489 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.261636e-01 | 0.487 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.276097e-01 | 0.485 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.276097e-01 | 0.485 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 3.276097e-01 | 0.485 | 0 | 0 |
| Translation | R-HSA-72766 | 3.298844e-01 | 0.482 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 3.299649e-01 | 0.482 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 3.346049e-01 | 0.475 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.346049e-01 | 0.475 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 3.375498e-01 | 0.472 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.415276e-01 | 0.467 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.415276e-01 | 0.467 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 3.415276e-01 | 0.467 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 3.451092e-01 | 0.462 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 3.483788e-01 | 0.458 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.483788e-01 | 0.458 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.483788e-01 | 0.458 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 3.483788e-01 | 0.458 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.483788e-01 | 0.458 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.483788e-01 | 0.458 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.483788e-01 | 0.458 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.483788e-01 | 0.458 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.488786e-01 | 0.457 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 3.526408e-01 | 0.453 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 3.526408e-01 | 0.453 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 3.526408e-01 | 0.453 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 3.538150e-01 | 0.451 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 3.551591e-01 | 0.450 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.551591e-01 | 0.450 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 3.551591e-01 | 0.450 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 3.563956e-01 | 0.448 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.618693e-01 | 0.441 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 3.618693e-01 | 0.441 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 3.618693e-01 | 0.441 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.618693e-01 | 0.441 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 3.685100e-01 | 0.434 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 3.685100e-01 | 0.434 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.685100e-01 | 0.434 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.685100e-01 | 0.434 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 3.685100e-01 | 0.434 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 3.750821e-01 | 0.426 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 3.750821e-01 | 0.426 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 3.750821e-01 | 0.426 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 3.750821e-01 | 0.426 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 3.779758e-01 | 0.423 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 3.815861e-01 | 0.418 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 3.815861e-01 | 0.418 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.815861e-01 | 0.418 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.836249e-01 | 0.416 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.880229e-01 | 0.411 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.880229e-01 | 0.411 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 3.880229e-01 | 0.411 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 3.880229e-01 | 0.411 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.880229e-01 | 0.411 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 3.943930e-01 | 0.404 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 3.943930e-01 | 0.404 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.943930e-01 | 0.404 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.943930e-01 | 0.404 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 3.943930e-01 | 0.404 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 3.943930e-01 | 0.404 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 3.943930e-01 | 0.404 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.971391e-01 | 0.401 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 4.006973e-01 | 0.397 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.006973e-01 | 0.397 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.006973e-01 | 0.397 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.006973e-01 | 0.397 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.006973e-01 | 0.397 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.006973e-01 | 0.397 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 4.069363e-01 | 0.390 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 4.116669e-01 | 0.385 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 4.116669e-01 | 0.385 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.131107e-01 | 0.384 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 4.143578e-01 | 0.383 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 4.192213e-01 | 0.378 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.192213e-01 | 0.378 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.192213e-01 | 0.378 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 4.224500e-01 | 0.374 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.252686e-01 | 0.371 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 4.252686e-01 | 0.371 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.252686e-01 | 0.371 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.252686e-01 | 0.371 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.252686e-01 | 0.371 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 4.252686e-01 | 0.371 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 4.252686e-01 | 0.371 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.252686e-01 | 0.371 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.312532e-01 | 0.365 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.312532e-01 | 0.365 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.312532e-01 | 0.365 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 4.312532e-01 | 0.365 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 4.312532e-01 | 0.365 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 4.312532e-01 | 0.365 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.312532e-01 | 0.365 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.371760e-01 | 0.359 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.401945e-01 | 0.356 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 4.488382e-01 | 0.348 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.488382e-01 | 0.348 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.488382e-01 | 0.348 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 4.545788e-01 | 0.342 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 4.602601e-01 | 0.337 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.602601e-01 | 0.337 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.602601e-01 | 0.337 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.658825e-01 | 0.332 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 4.658825e-01 | 0.332 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.658825e-01 | 0.332 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.658825e-01 | 0.332 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 4.714467e-01 | 0.327 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 4.714467e-01 | 0.327 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 4.714467e-01 | 0.327 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 4.714467e-01 | 0.327 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 4.768836e-01 | 0.322 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 4.769532e-01 | 0.322 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 4.769532e-01 | 0.322 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 4.824028e-01 | 0.317 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 4.824028e-01 | 0.317 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.877959e-01 | 0.312 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 4.877959e-01 | 0.312 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.877959e-01 | 0.312 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.877959e-01 | 0.312 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.931331e-01 | 0.307 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.984151e-01 | 0.302 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 5.036423e-01 | 0.298 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.036423e-01 | 0.298 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.036423e-01 | 0.298 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 5.088154e-01 | 0.293 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 5.139348e-01 | 0.289 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.139348e-01 | 0.289 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 5.139348e-01 | 0.289 | 0 | 0 |
| S Phase | R-HSA-69242 | 5.177432e-01 | 0.286 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.190013e-01 | 0.285 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 5.190013e-01 | 0.285 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.190013e-01 | 0.285 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 5.240152e-01 | 0.281 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.240152e-01 | 0.281 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 5.289772e-01 | 0.277 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 5.289772e-01 | 0.277 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.289772e-01 | 0.277 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 5.336444e-01 | 0.273 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.338877e-01 | 0.273 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.435567e-01 | 0.265 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 5.483161e-01 | 0.261 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.483161e-01 | 0.261 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.576875e-01 | 0.254 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.576875e-01 | 0.254 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.576875e-01 | 0.254 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.623005e-01 | 0.250 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.623005e-01 | 0.250 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 5.623005e-01 | 0.250 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 5.623005e-01 | 0.250 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 5.623005e-01 | 0.250 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 5.623005e-01 | 0.250 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 5.668656e-01 | 0.247 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.668656e-01 | 0.247 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 5.668656e-01 | 0.247 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 5.713834e-01 | 0.243 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.758543e-01 | 0.240 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 5.758543e-01 | 0.240 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.802789e-01 | 0.236 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.846576e-01 | 0.233 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 5.932793e-01 | 0.227 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 5.932793e-01 | 0.227 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 5.975232e-01 | 0.224 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.975232e-01 | 0.224 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 5.975232e-01 | 0.224 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 6.017230e-01 | 0.221 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 6.021029e-01 | 0.220 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 6.052819e-01 | 0.218 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 6.058793e-01 | 0.218 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 6.140630e-01 | 0.212 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.140630e-01 | 0.212 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 6.220777e-01 | 0.206 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.220777e-01 | 0.206 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 6.260228e-01 | 0.203 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 6.299269e-01 | 0.201 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.413979e-01 | 0.193 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 6.476830e-01 | 0.189 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 6.561446e-01 | 0.183 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 6.737329e-01 | 0.172 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 6.771418e-01 | 0.169 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.805152e-01 | 0.167 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 6.844019e-01 | 0.165 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 6.871573e-01 | 0.163 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.904267e-01 | 0.161 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 7.114860e-01 | 0.148 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 7.179477e-01 | 0.144 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.271079e-01 | 0.138 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 7.345897e-01 | 0.134 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 7.383478e-01 | 0.132 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.464746e-01 | 0.127 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 7.484636e-01 | 0.126 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 7.517526e-01 | 0.124 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 7.569214e-01 | 0.121 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.690130e-01 | 0.114 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 7.857625e-01 | 0.105 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.880065e-01 | 0.103 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 7.880065e-01 | 0.103 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 7.988805e-01 | 0.098 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 7.999984e-01 | 0.097 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 8.051368e-01 | 0.094 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.131786e-01 | 0.090 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.170750e-01 | 0.088 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 8.227685e-01 | 0.085 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 8.246269e-01 | 0.084 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.264659e-01 | 0.083 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 8.282858e-01 | 0.082 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.300867e-01 | 0.081 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.318688e-01 | 0.080 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 8.405046e-01 | 0.075 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 8.424949e-01 | 0.074 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.564752e-01 | 0.067 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.624089e-01 | 0.064 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 8.813205e-01 | 0.055 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 8.897834e-01 | 0.051 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 8.920892e-01 | 0.050 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.114963e-01 | 0.040 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.254691e-01 | 0.034 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.329868e-01 | 0.030 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.496806e-01 | 0.022 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.566355e-01 | 0.019 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.584408e-01 | 0.018 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 9.638244e-01 | 0.016 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.734250e-01 | 0.012 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.778322e-01 | 0.010 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.879480e-01 | 0.005 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.903795e-01 | 0.004 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.912627e-01 | 0.004 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.953469e-01 | 0.002 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.968913e-01 | 0.001 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 9.997116e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.997505e-01 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 9.999823e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999889e-01 | 0.000 | 0 | 0 |